Abstract 139P
Background
No specialized prognosis model for gastric cancer patients with peritoneal metastasis (GCPM) exists for intraoperative clinical decision-making. This study aims to establish a new prognostic model to provide individual treatment decisions for GCPM.
Methods
This retrospective analysis included 324 GCPM diagnosed pathologically by laparoscopy from January 2007 to January 2018 who were randomly assigned to different sets (227 in the training set and 97 in the validation set). A nomogram was established from preoperative and intraoperative variables determined by the Cox model. The peritoneal metastasis nomogram (PMN), was compared with the 15th peritoneal metastasis staging system (P1abc) for its predictive ability and clinical applicability.
Results
The median survival time was 8 (range, 1-90) months. In the training set, each PMN substage had significantly different survival curves (P<0.001), and the PMN was superior to P1abc based on the results of time-dependent receiver operating characteristic curve, C-index, Akaike information criterion and likelihood ratio chi-square analyses. In the validation set, the PMN was also better than P1abc in terms of its predictive ability. Of the PMN1 patients, those undergoing palliative resection (PR) had better OS than those undergoing exploratory surgery (ES) (P<0.05). Among the patients undergoing ES, those who received chemotherapy exhibited better OS than those who did not (P<0.05). Among the patients with PR, only PMN1 patients exhibited better OS following chemotherapy (P<0.05).
Conclusions
We developed and validated a simple, specific peritoneal metastasis model for GCPM that can predict prognosis well and guide treatment decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session